Sub–optimal postprandial blood glucose level in diabetics attending the outpatient clinic of a University Hospital

Daad H. Akbar, FRCP, FACP.

ABSTRACT

Objectives: To determine the frequency of diabetic patients who attained the optimal postprandial blood glucose level.

Methods: Cross-sectional study of type-2 diabetic patients being followed at the medical outpatient clinic of King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia, from January 1999 to December 2001. Patients were classified according to postprandial blood glucose level into 3-categories; group-1 (<9mmol/l), group-2 (9.1-10 mmol/l), group-3 (>10 mmol/l). Other data such as age, sex, duration of diabetes, presence of hypertension, hyperlipidemia, smoking, obesity, ischemic heart disease was recorded as well as mortality.

Results: A total of 443 patients were studied with mean age of 55 years and equal male to female ratio. The mean 2-hour postprandial blood glucose level was 14 mmol/l. The majority of patients were in group-3 (71%), while group-1 was 22% and group-2 was 7%. Patients with high 2-hour postprandial blood glucose (group-3) have a higher prevalence of hypertension [120/315 (38%) versus 31/97 (32%) $p=0.01$], hyperlipidemia [72/315 (23%) versus 13/97 (13%) $p=0.02$], obesity [79/315 (25%) versus 18/97 (19%) $p=0.04$], ischemic heart disease [72/315 (23%) versus 16/97 (17%) $p=0.04$] and mortality [35/315 (11%) versus 8/97 (8%) $p=0.06$] compared to those with controlled level (group-1).

Conclusion: A low frequency of diabetics attained the optimal 2-hour postprandial blood glucose level. Action should be taken on this crucial issue for the optimal management of diabetes.

Saudi Med J 2003; Vol. 24 (10): 1109-1112

Diabetes mellitus has recently been classified as a major independent risk factor for the development of coronary heart disease.[1] Patients with diabetes have increased risk of cardiovascular morbidity and mortality. Diabetic patients without previous myocardial infarction have outcomes similar to non-diabetic patients who have a previous myocardial infarction.[2] The importance of postprandial blood glucose is evident in the literature. Postprandial hyperglycemia (PPH) has been associated with increased risk of microvascular and macrovascular complications.[3-7] The Diabetes Intervention Study had showed that PPH was an independent risk factor for myocardial infarction and cardiac death.[8] We aim in our study to determine the frequency of diabetic patients, attending the outpatient medical clinic of King Abdul-Aziz University Hospital, Jeddah, Kingdom of Saudi Arabia (KSA), with optimal postprandial blood glucose level.

Methods. A cross-sectional study in which type-2 diabetic patients being followed in the outpatient medical clinic of King Abdul-Aziz University Hospital, Jeddah, KSA, from January 1999 to December 2001 were studied. The mean level of the last 2 fasting and 2-hours postprandial blood glucose (which were

measured on an average of 6-12 weeks apart) was recorded. According to the expert committee report of the American Diabetes Association in 1999,[9] the goal 2-hour postprandial blood glucose has to be 160 mg/dl (8.8 mmol/l) and action should be taken if it reaches 180 mg/dl (10 mmol/l); for fasting it is 120mg/dl (6.6 mmol/l) with action to be taken if it reaches 140 mg/dl (7.7 mmol/l). In 2002 a recommendation for a wider range for fasting 90-130 mg/dl (5-7 mmol/l)] was proposed and action suggested if it reached >150 mg/dl (8.3 mmol/l) and for bed time glucose it was 110-150 mg/dl (6-8.3mmol/l) and >180mg/dl (10 mmol/l).[10] As we are using mmol/l unit for the measurement of plasma glucose in our hospital we classify the patients according to the 2-hours postprandial blood glucose level into 3-categories; goal <9 mmol/l, border line 9.1-10 mmol/l, poor >10 mmol/l. while for fasting; goal <7 mmol/l, borderline 7.1-8 mmol/l, poor >8 mmol/l. The following data was also collected from the study group; age, sex, body mass index (BMI), duration of diabetes, type of treatment (diet, oral hypoglycemic agents, insulin or combined), presence of hypertension (defined as blood pressure >140/90 mm Hg or if the patient is known hypertensive), hyperlipidemia (defined as low density lipoprotein (LDL) >2.6 mmol/l, high density lipoprotein (HDL) <1.1 mmol/l, triglyceride >1.7 mmol/l), history of smoking, history of ischemic heart disease (assessed by patient's history or changes on electrophysiological studies), and mortality. The frequency of diabetic patients in each group was calculated, and the relations between them and cardiovascular risk factors and mortality were determined. Statistical analysis was carried out using the Statistical Package for Social Sciences 9.1 software. Values as mean $\pm$ standard deviation were given for quantitative data and frequency for categorical variables. Chi-square was used to analyze group differences for categorical variables. For continuous variables t- test was used when comparing 2 groups. *P*-value <0.05 was considered significant.

Results. A total of 443 patients were enrolled in the study. Out of which 217 (49%) were males. The mean age was 54.8 ± 16.2 years and the mean BMI 25.5 ± 3.6 m²/kg. Two hundred and seventy (61% were on oral hypoglycemic agents, 133/443 (30%) on insulin, 27/443 (6%) on diet and 13/443 (3%) on combined treatment. The mean fasting blood glucose for the study group was 9.7 ± 3.2 mmol/l while for 2-hour postprandial blood glucose it was 13.75 ± 5.5 mmol/l. A low frequency of patients attained the goal for fasting and 2-hour postprandial blood glucose level and most of them lie in the poor control group (**Table 1**). No statistically significant difference was detected between the goal group and the poor control group of 2-hour postprandial blood glucose regarding age or sex distribution while patients with poor control are more likely to have associated cardiovascular risk factors, ischemic heart disease and poor outcome (**Table 2**). Patients with poor 2-hour postprandial blood glucose control are also more

Table 1 - Frequency of fasting and postprandial blood glucose in different groups.

Fasting blood glucose	Group 1 (<7mmol/l) n (%)		Group 2 (7.1-8 mmol/l) n (%)		Group 3 (>8 mmol/l) n (%)	
	168 (38)		49 (11)		226 (51)	
Postprandial blood glucose	Group 1 (<9mmol/l)		Group 2 (9.1-10 mmol/l)		Group 3 (>10 mmol/l)	
	97 (22)		31 (7)		315 (71)	

Table 2 - Relationship between postprandial hyperglycemia (Group 1 and Group 3) and different variables.

Variable	Group 1 (N=97)	Group 3 (N=315)	*p*-value
Age in years (mean ± SD)	54±16	53±15	0.6
Male:female ratio	1:1.1	1:1.1	0.9
Duration of diabetes (in years)	8±6	9.5±8	0.1
Hypertension n (%)	31 (32)	120 (38)	0.01
Hyperlipidemia n (%)	13 (13)	72 (23)	0.02
Obesity (BMI>27 m²/kg) n (%)	18 (19)	79 (25)	0.04
Smoking n (%)	34 (35)	110 (35)	0.4
Ischemic heart disease n (%)	16 (17)	72 (23)	0.01
Mortality n (%)	8 (8)	8 (8)	0.06
SD - standard deviation; BMI - body mass index			

likely to have poor fasting blood glucose control compared to goal control; 75/97 (77%) of patients with goal 2-hour postprandial blood glucose also had goal fasting blood glucose compared to 17/97 (18%) with poor fasting blood glucose (*p*<0.001), while 202/315 (64%) of patients with poor 2-hour postprandial blood glucose had poor fasting blood glucose versus 76/315 (24%) who have goal fasting blood glucose (*p*<0.001).

Discussion. Despite the significant advances in the management of coronary heart disease and the decline in mortality of cardiovascular disease in the general population by 36% in men and 27% in women over the last decade, diabetic patients continue to have a high incidence of coronary heart disease and poor clinical outcome. The decline in mortality in diabetics was only 13% in diabetic men, and it increased by 23% in diabetic women.[11,12] Epidemiological and clinical evidence is mounting on the important contribution of postprandial blood glucose excursions to overall glycemic control and the association between postprandial hyperglycemia and many of the major micro- and macrovascular complications of diabetes, including retinopathy, nephropathy, and cardiovascular disease.[13-17] The risk of cardiovascular disease and all-cause mortality increases with increasing postprandial blood glucose values,[18-21] in addition, as indicated by the Oslo study, PPH was a predictor of fatal stroke in diabetics and the risk

increased by 13% for each 18 mg/dl elevation in postprandial blood glucose level.[22] Another study documented that PPH is an independent risk factor for peripheral vascular disease.[23] Recent reports suggested an association between PPH and intellectual function in elderly Alzheimer's patients.[24] Our study showed a higher prevalence of ischemic heart disease and higher mortality in patients with high PPH compared to those with low levels. Several mechanisms had been proposed for the increased risk of complications that are seen in patients with PPH. The PPH is associated with hyperinsulinemia and higher plasma level of triglyceride, chylomicrons, chylomicron remnants and free fatty acids. Hyperinsulinemia has been shown to be a risk factor for cardiovascular events. The Paris prospective study found that postprandial hyperinsulinemia was a predictor for fatal cardiovascular disease.[25] Similarly, the Helsinki Policeman Study revealed an independent association between fatal and nonfatal cardiovascular events and postprandial hyperinsulinemia.[26] High concentration of free fatty acid is associated with endothelial dysfunction.[27] High level of triglycerides is associated with low levels of HDL and preponderance of small dense LDL particles. Studies have shown that hypertriglyceridemia predicts the development of coronary artery disease and is associated with increased carotid artery atherosclerosis.[28,29] Excessive postprandial blood glucose stimulates production of free radicals which are also another factor involved in the atherosclerotic process.[30] Postprandial hyperglycemia has been associated with transient hypercoagulability resulting from increased thrombin production and decreased fibrinogen breakdown.[31] Goal postprandial blood glucose level (<9 mmol/l) has been found in only 22% of our diabetic patients, while the majority (71%) had levels more than 10 mmol/l. Poor glycemic control is a global problem. Harris et al[32] reported a rate of poor glycemic control (hemoglobin A1c >8%) in 50% of non-Hispanic black women and 45% in Mexican males. Similar results were reported by Schiel et al from Germany.[33] While Azab[34] reported poor fasting blood glucose control (>10 mmol/l) in 49% of diabetic patients attending Primary Health Care Centers in Riyadh, KSA, this poor glycemic control could be a result of poor compliance either due to the patients being unable to afford to buy the medications, lack of knowledge about the importance of good glycemic control or poor compliance with long time medications. Efforts should be carried out for better patients' education through different media; supply of medication and proper follow up.

Clearly PPH is strongly associated with cardiovascular risk factors such as hypertension, hyperlipidemia, and obesity. Epidemiological studies suggest that postprandial rather than fasting glucose levels may better predict individuals at increased risk of developing complications associated with hyperglycemia.[35,36] Avignon and colleagues[37] showed that postprandial glucose levels were better predictors of overall glycemic control and were correlated better with A1c than fasting glucose levels. For patients with diabetes, postprandial blood glucose excursions can contribute 20-40% to the elevation of A1c above baseline. The United Kingdom Prospective Diabetes Study Group has clearly demonstrated that reduction of A1c is significantly associated with reduction in the risk of microvascular complications.[14] The full clinical significance of chronic hyperglycemia is well documented in studies that show the many complications associated with continuously increased blood glucose levels. The contribution of postprandial hyperglycemia to these complications is now emerging from studies that indicate that there may be effects of acute hyperglycemia on the development of retinopathy, neuropathy, nephropathy, and especially cardiovascular disease. Postprandial hyperglycemia is a neglected cardiovascular risk factor in diabetics. Based on evidence of the importance of postprandial blood glucose excursions on evaluation of hyperglycemia, the monitoring of postprandial blood glucose excursions and treatment of postprandial hyperglycemia, are critical to the optimal management of diabetes.

References

1. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard B, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* 1999; 100: 1134-1146.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary artery disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229-234.
3. de Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. *N Engl J Med* 1995; 333: 1237-1241.
4. McCance DR, Hanson RL, Charles M, Jacobsson LT, Pettitt DJ, Bennett PH, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations in diagnostic methods for diabetes. *BMJ* 1994; 308: 1323-1328.
5. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. *Diabetes Care* 1997; 20: 785-791.
6. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry Study. *Diabetes Care* 1997; 20: 163-169.
7. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. *Diabetes* 1987; 36: 689-692.
8. Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. *Diabet Med* 1997; 4 Suppl 3: S6-S11.
9. American Diabetes Association: clinical practice recommendations 1999. *Diabetes Care* 1999; 22 Suppl 1: S1-114.
10. American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002; 25 Suppl 1: S1-147.
11. McGuire DK, Granger CB. Diabetes and ischemic heart disease. *Am Heart J* 1999; 138: S366-S375.

12. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. *JAMA* 1999; 281: 1291-1297.

13. Diabetes Control and Complications Trial (DCCT) Study Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). *Diabetologia* 1998; 41: 416-423.

14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998; 352: 837-853.

15. Diabetes Control and Complications Trial (DCCT) Study Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. *Diabetes* 1996; 45: 1289-1298.

16. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. *Diabetes Res Clin Pract* 1995; 28: 103-117.

17. Diabetes Control and Complications Trial (DCCT) Study Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-986.

18. Balkau B, Bertrais S, Ducimetiere P, Eschwege E. Is there a glycemic threshold for mortality risk? *Diabetes Care* 1999; 22: 696-699.

19. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. *Diabetologia* 1999; 42: 926-931.

20. European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. *Diabetologia* 1999; 42: 647-654.

21. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. *Circulation* 1995; 91: 2591-2599.

22. Håheim LL, Holme I, Hjermann I, Leren P. Nonfasting serum glucose and the risk of fatal stroke in diabetic and nondiabetic subjects. 18-year follow-up of the Oslo Study. *Stroke* 1995; 26: 774-777.

23. Beks PJ, Mackaay AJC, de Neeling JND, de Vries H, Bouter LM, Heine RJ. Peripheral arterial disease in relation to glycaemic level in an elderly caucasian population: the Hoorn Study. *Diabetologia* 1995; 38: 86-96.

24. Stolk RP, Breteler MMB, Ott A, Pols HA, Lamberts SW, Grobbee DE, et al. Insulin and cognitive function in an elderly population. The Rotterdam Study. *Diabetes Care* 1997; 20: 792-795.

25. Fontbonne AM, Eschwège EM. Insulin and cardiovasculardisease. Paris Prospective Study. *Diabetes Care* 1991; 14: 461-469.

26. Pyörälä K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. *Acta Med Scand* 1985; 701 Suppl: 38-52.

27. Groot PHE, van Stiphout WAHJ, Krauss XH, Jansen H, van Tol A, van Ramshorst E, et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. *Arterioscler Thromb* 1991; 11: 653-662.

28. Patsch JR, Miesenböck G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease. studies in the postprandial state. *Arterioscler Thromb* 1992; 12: 1336-1345.

29. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W for the ARIC Investigators: Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. *Arterioscler Thromb Vasc Biol* 1995; 15: 2122-2129.

30. Habib MP, Dickerson FD, Mooradian AD. Effect of diabetes, insulin, and glucose load on lipid peroxidation in the rat. *Metabolism* 1994; 43: 1442-1445

31. Ceriello A, Quatraro A, Marchi E, Barbanti M, Giugliano D. Impaired fibrinolytic response to increased thrombin activation in type 1 diabetes mellitus: effects of the glycosaminoglycan sulodexide. *Diabetes Metab* 1993; 19: 225-229.

32. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. *Diabetes Care* 1999; 22: 403-408.

33. Schiel R, Blum M, Muller UA, Kohler S, Kademann A, Strobel J, et al. Screening for people with diabetes mellitus for poor blood glucose control in an ophthalmological laser clinic. *Diabetes Res Clin Pract* 2001; 53: 173-179.

34. Azab AS. Glycemic control among diabetic patients. *Saudi Med J* 2001; 22: 407-409.

35. European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. *Lancet* 1999; 354: 617-621.

36. European Diabetes Epidemiology Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. *Diabetologia* 1999; 42: 647-654.

37. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma